Phaseline

Companies › OncoVerity

OncoVerity: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cusatuzumab
CD70 antigen inhibitor
CD70Phase 2Leukemia, Myeloid, AcuteJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06384261CusatuzumabPhase 2Leukemia, Myeloid, AcuteOncologyJan 2027
NCT04023526CusatuzumabPhase 2Leukemia, Myeloid, AcuteOncologyMay 2027
NCT04150887CusatuzumabPhase 1Leukemia, Myeloid, AcuteOncologyMay 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CD70 (1)

Companies with the same targets

Chongqing Precision Biotech Allogene Therapeutics Pfizer Beijing Biotech Alpine Immune Sciences Qilu Pharmaceutical Hrain Biotechnology Adicet Therapeutics

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.